Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Charles L Raison

Showing results (111-120 of 140) with videos related to

Pageof 14
Sort By:
Brain, Behavior, and Immunity|April 27, 2024
The antidepressant effect of whole-body hyperthermia is associated with the classical interleukin-6 signaling pathwayNaoise Mac Giollabhui, Christopher A Lowry, Maren Nyer, et al.
Journal of Health Care Chaplaincy|February 14, 2020
Compassion Meditation Training for Hospital Chaplain Residents: A Pilot StudyMarcia J Ash, Elizabeth Reisinger Walker, Ralph J DiClemente, et al.
International Review of Psychiatry (Abingdon, England)|February 21, 2025
Leveraging meditation research for the study of psychedelic-related adverse effectsRoman Palitsky, Nicholas K Canby, Nicholas T Van Dam, et al.
Journal of Health Care Chaplaincy|April 15, 2024
A mixed-method evaluation of implementation determinants for chaplain intervention in a hospital settingJennifer S Mascaro, Marianne P Florian, Erin Brauer, et al.
Advances in Integrative Medicine|August 20, 2025
Treating major depressive disorder with an integrated mind-body intervention: Whole-body hyperthermia and cognitive behavioral therapy, a case reportChelsea J Siwik, Anoushka Chowdhary, Claudine Anglo, et al.
Translational Psychiatry|February 13, 2026
Electrophysiological effects of psilocybin co-administered with midazolamMichael H Sutherland, Christopher R Nicholas, Richard C Lennertz, et al.
Translational Psychiatry|September 12, 2024
Co-administration of midazolam and psilocybin: differential effects on subjective quality versus memory of the psychedelic experienceChristopher R Nicholas, Matthew I Banks, Richard C Lennertz, et al.
Journal of Psychopharmacology (Oxford, England)|July 31, 2024
A framework for assessment of adverse events occurring in psychedelic-assisted therapiesRoman Palitsky, Deanna M Kaplan, John Perna, et al.
Translational Psychiatry|April 21, 2023
Association of plasma cytokines and antidepressant response following mild-intensity whole-body hyperthermia in major depressive disorderMichael C Flux, David G Smith, John J B Allen, et al.
Translational Psychiatry|January 19, 2021
The IL-6 antagonist tocilizumab is associated with worse depression and related symptoms in the medically illJennifer M Knight, Erin S Costanzo, Suraj Singh, et al.
Pageof 14

Showing results (111-120 of 140) with videos related to

Sort By:
Pageof 14
Brain, Behavior, and Immunity|April 27, 2024
The antidepressant effect of whole-body hyperthermia is associated with the classical interleukin-6 signaling pathwayNaoise Mac Giollabhui, Christopher A Lowry, Maren Nyer, et al.
Journal of Health Care Chaplaincy|February 14, 2020
Compassion Meditation Training for Hospital Chaplain Residents: A Pilot StudyMarcia J Ash, Elizabeth Reisinger Walker, Ralph J DiClemente, et al.
International Review of Psychiatry (Abingdon, England)|February 21, 2025
Leveraging meditation research for the study of psychedelic-related adverse effectsRoman Palitsky, Nicholas K Canby, Nicholas T Van Dam, et al.
Journal of Health Care Chaplaincy|April 15, 2024
A mixed-method evaluation of implementation determinants for chaplain intervention in a hospital settingJennifer S Mascaro, Marianne P Florian, Erin Brauer, et al.
Advances in Integrative Medicine|August 20, 2025
Treating major depressive disorder with an integrated mind-body intervention: Whole-body hyperthermia and cognitive behavioral therapy, a case reportChelsea J Siwik, Anoushka Chowdhary, Claudine Anglo, et al.
Translational Psychiatry|February 13, 2026
Electrophysiological effects of psilocybin co-administered with midazolamMichael H Sutherland, Christopher R Nicholas, Richard C Lennertz, et al.
Translational Psychiatry|September 12, 2024
Co-administration of midazolam and psilocybin: differential effects on subjective quality versus memory of the psychedelic experienceChristopher R Nicholas, Matthew I Banks, Richard C Lennertz, et al.
Journal of Psychopharmacology (Oxford, England)|July 31, 2024
A framework for assessment of adverse events occurring in psychedelic-assisted therapiesRoman Palitsky, Deanna M Kaplan, John Perna, et al.
Translational Psychiatry|April 21, 2023
Association of plasma cytokines and antidepressant response following mild-intensity whole-body hyperthermia in major depressive disorderMichael C Flux, David G Smith, John J B Allen, et al.
Translational Psychiatry|January 19, 2021
The IL-6 antagonist tocilizumab is associated with worse depression and related symptoms in the medically illJennifer M Knight, Erin S Costanzo, Suraj Singh, et al.
Pageof 14